GeneDx (NASDAQ:WGS) Given New $170.00 Price Target at BTIG Research

GeneDx (NASDAQ:WGS) had its target price reduced by BTIG Research from $200.00 to $170.00 in a report released on Tuesday, MarketBeat Ratings reports. They currently have a buy rating on the stock.

WGS has been the subject of a number of other reports. Guggenheim reissued a “buy” rating and set a $170.00 price objective (up from $115.00) on shares of GeneDx in a research note on Wednesday, October 29th. Wall Street Zen downgraded GeneDx from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Jefferies Financial Group set a $150.00 price target on GeneDx in a report on Monday. Canaccord Genuity Group increased their price objective on GeneDx from $160.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Finally, Wells Fargo & Company raised shares of GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 target price for the company in a research note on Monday, February 9th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, GeneDx has an average rating of “Moderate Buy” and a consensus price target of $150.71.

GeneDx Stock Down 7.3%

GeneDx stock opened at $80.70 on Tuesday. GeneDx has a fifty-two week low of $55.17 and a fifty-two week high of $170.87. The firm has a market capitalization of $2.33 billion, a price-to-earnings ratio of -107.60 and a beta of 2.00. The stock’s fifty day moving average is $109.90 and its two-hundred day moving average is $124.48. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.59 and a current ratio of 2.71.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Monday, February 23rd. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.11 by $0.03. The business had revenue of $120.99 million for the quarter, compared to analyst estimates of $120.80 million. GeneDx had a negative net margin of 4.92% and a positive return on equity of 15.17%. Analysts predict that GeneDx will post 0.97 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Katherine Stueland sold 10,857 shares of the stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $143.89, for a total transaction of $1,562,213.73. Following the transaction, the chief executive officer directly owned 14,237 shares in the company, valued at $2,048,561.93. This represents a 43.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Kevin Feeley sold 3,855 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $143.87, for a total transaction of $554,618.85. Following the completion of the sale, the chief financial officer owned 8,731 shares of the company’s stock, valued at approximately $1,256,128.97. The trade was a 30.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 30,961 shares of company stock worth $3,933,831. 29.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On GeneDx

Several hedge funds and other institutional investors have recently modified their holdings of WGS. Goldman Sachs Group Inc. raised its holdings in GeneDx by 4.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,220,502 shares of the company’s stock valued at $158,738,000 after buying an additional 52,322 shares during the period. Vanguard Group Inc. increased its position in shares of GeneDx by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 1,189,069 shares of the company’s stock worth $154,650,000 after acquiring an additional 18,647 shares in the last quarter. Franklin Resources Inc. increased its position in shares of GeneDx by 60.4% in the fourth quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock worth $142,154,000 after acquiring an additional 411,607 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in shares of GeneDx by 87.1% in the 4th quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock valued at $132,435,000 after acquiring an additional 474,167 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of GeneDx by 59.2% during the 4th quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock valued at $102,288,000 after acquiring an additional 292,394 shares in the last quarter. 61.72% of the stock is owned by institutional investors and hedge funds.

More GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Q4 revenue and EPS slightly beat expectations — reported $120.99M revenue and $0.14 EPS vs. consensus ~$120.8M and $0.11, a concrete data beat that supports growth traction. Zacks: Q4 Earnings and Revenues Beat
• Positive Sentiment: Company reaffirmed full‑year 2026 guidance and provided an investor presentation/earnings call with details — this reduces uncertainty about management’s outlook. BusinessWire: Q4 & Full‑Year Results
• Positive Sentiment: Street upgrades and constructive notes: Seeking Alpha upgraded WGS to Buy, arguing operational improvements and a clearer growth plan (management plans to markedly expand commercial footprint in 2026) make the story investable again. Seeking Alpha: Rating Upgrade
• Neutral Sentiment: BTIG lowered its price target from $200 to $170 but kept a Buy rating — shows continued analyst conviction but with a more conservative valuation view. The Fly / Benzinga: BTIG Lowers PT
• Negative Sentiment: Some coverage framed the quarter as “mixed” (revenue OK but earnings/near‑term profitability weaker), which can dampen enthusiasm — EPS is well below last year’s level, and net margins remain thin. Investing.com: Mixed Q4 Results
• Negative Sentiment: Management’s stated strategy to prioritize aggressive commercial expansion in 2026 (to capture growth) implies near‑term margin pressure and higher operating investment — a tradeoff that can make investors sell now and wait for 2027 proof of scale. Seeking Alpha: Growth vs Margins

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.